Laurus Labs · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Sequential CDMO revenue declined 13% in Q3 despite full-year 50%+ growth guidance. Analysts questioned whether Q3 represents a sustainable quarterly base or lumpiness from once/twice-yearly supply patterns. Management deflected quarterly analysis, recommending annual view only.
ADC GMP facility ($25 million allocated) and gene therapy process development labs will not generate meaningful revenues for at least 24 months, with all expenditures expensed through P&L rather than capitalized.
Bio revenues will stagnate until the new fermentation facility at WSAC (400+ kiloliters Phase I) becomes operational toward end of 2026, with asset turnover currently constrained at 0.91x.
Q3 cash conversion hit 113% of EBITDA partly due to customer advances, which management acknowledged as not fully sustainable. Analyst questioned longer-term sustainable conversion rate assumption of 80%+ versus historical 63%.
